Pfizer Exec Booed During White House Appearance
The future of the CDC’s vaccine advisory committee seems uncertain: A scheduled February meeting for the ACIP, which advises ...
As the second Trump administration settles in, the U.S.' top pharmaceutical trade group is drafting its ambitions for the ...
Pfizer may appeal to income investors, but growth prospects remain uncertain. Read why PFE stock might struggle to gain ...
Albert Bourla, Pfizer CEO, joins CNBC's Angelica Peebles and 'Closing Bell Overtime' to talk the impact of tariffs, Pfizer's ...
The FDA determined that Novo Nordisk’s obesity and diabetes drugs are no longer in short supply. Elsewhere, Concentra made a ...
Pfizer's strong Q4 2024 results showcase growth in cancer drugs and Vyndaqel sales. Learn why PFE stock is a top pick for ...
The meeting, which will include Pfizer CEO Albert Bourla as the newly named board of directors’ chair, will reportedly cover ...
Pfizer CEO Albert Bourla said its manufacturing business could be vulnerable from President Donald Trump’s tariffs in Europe ...
As well as, falling in tandem with the release of Pfizer’s annual earnings report, which reflected revenues of $63.6 billion. In the announcement, Bourla stated: “I’m excited for what’s ...
Pfizer Inc. is vulnerable to the possibility that President Donald Trump will place tariffs on the European Union, where the ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback